Saturday 17 October 2026
Export IMUX’s income statement to Excel — free account
Immunic, Inc.
IMUX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 60.0% and free cash flow fell 26.8%, each against the same quarter a year earlier.
6.97
0.13
−1.83%
Follow IMUX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (138.17%) | (142.91%) | (1,653.15%) | (398.50%) |
+8 more TTM periods Free account |
|
| (101.15%) | (99.20%) | (299.36%) | (195.41%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(87.61%) | (69.08%) | 1,360.76% | (1,047.86%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.07) | (2.70) | (5.52) | (4.62) | |
Free Cash Flow |
(88.05) | (81.45) | (85.97) | (89.64) | |
Capital Expenditures |
(0.33) | (0.12) | (0.16) | (0.15) | |
| Other line items | |||||
Cash ROIC |
(31.15%) | (24.11%) | (975.79%) | (196.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.78 | 0.88 | 0.87 | |
Depreciation/Fixed assets |
0.19 | 0.28 | 0.28 | 0.25 | |
Capex/Depreciation |
(2.21) | (0.73) | (0.96) | (0.95) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.06) | (2.70) | (5.51) | (4.62) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates